Table 3. Open in new tab Logistic...

Factor	SD in Women (n = 36)^a	SD in Men (n = 13)^a	ED in Men (n = 22)^b
Age	1.03 (0.99-1.07)	.15	1.00 (0.96-1.05)	.88	1.02 (0.98-1.07)	.26
Body mass index	0.99 (0.91-1.08)	.81	0.93 (0.79-1.11)	.42	0.96 (0.85-1.13)	.77
Long-term relationship (≥1 y)	1.56 (0.09-26.47)	.76	>1000 (0.00 -)	1.00	>1000 (0.00 -)	1.00
Crohn’s disease vs ulcerative colitis	0.77 (0.25-2.37)	.65	1.34 (0.38-4.73)	.65	2.26 (0.75-6.83)	.15
Disease duration	1.04 (0.98-1.09)	.19	0.89 (0.94-1.06)	.89	1.00 (0.95-1.05)	.92
Current corticosteroid use	1.08 (0.23-5.01)	.93	2.00 (0.43-9.42)	.38	0.82 (0.18-3.65)	.79
Corticosteroid use in year	0.78 (0.26-2.35)	.65	2.25 (0.60-8.41)	.23	1.69 (0.51-5.56)	.39
Immunomodulator use	0.48 (0.16-1.42)	.18	0.81 (0.23-2.87)	.75	0.91 (0.31-2.65)	.86
Anti-tumor necrosis factor use	1.39 (0.41-4.74)	.60	1.67 (0.37-7.65)	.51	1.15 (0.29-4.62)	.85
Psychotropic medication use	1.80 (0.54-6.03)	.34	3.15 (0.61-16.37)	.17	2.75 (0.55-13.67)	.22
Antihypertensive use	—	—	1.43 (0.32-6.38)	.64	2.64 (0.70-10.03)	.15
Opiate use	0.62 (0.08-4.72)	.64	—	—	—	—
Other major comorbidityc	1.39 (0.41-4.74)	.60	3.64 (0.81-16.33)	.09	2.43 (0.58-10.23)	.23
Prior diagnosis of anxiety or depression	1.80 (0.54-6.03)	.34	2.61 (0.39-17.56)	.33	2.76 (0.42-18.01)	.29
Irritable bowel syndrome	1.69 (0.30-9.56)	.55	—	—	—	—
Current smoking	0.61 (0.11-3.30)	.56	4.88 (0.28-86.35)	.28	1.85 (0.11-31.12)	.67
Excess alcohol intaked	1.44 (0.12-17.12)	.77	—	—	—	—
Previous abdominal surgery	5.33 (1.34-21.20)	.02^e	0.76 (0.18-3.22)	.71	0.70 (0.21-2.36)	.56
Hormonal contraceptive use	0.77 (0.18-3.21)	.72	—	—	—	—
Current or previous perianal disease	6.56 (0.72-59.85)	.10	0.75 (0.07-7.88)	.81	0.25 (0.03-2.53)	.24
Baseline Hb	0.98 (0.93-1.02)	.30	0.94 (0.89-0.98)	.01^e	0.95 (0.90-0.99)	.02
Elevated baseline fCal (≥200 μg/g)	1.19 (0.39-3.59)	.76	0.86 (0.24-3.03)	.81	0.81 (0.27-2.41)	.70
Active IBD symptoms (HBI ≥5, SCCAI ≥5)	3.21 (1.03-9.98)	.04^e	0.68 (0.19-2.40)	.55	0.98 (0.34-2.83)	.97
Active endoscopic disease (SES-CD ≥3, UCEIS ≥2)	1.62 (0.56-4.70)	.37	0.44 (0.12-1.55)	.20	0.57 (0.20-1.65)	.30
Reduced quality of life (IBDQ-32 <169)	2.29 (0.76-6.88)	.139	1.29 (0.36-4.63)	.69	1.64 (0.54-4.94)	.38
Moderate or severe stress symptoms (PSS-10 ≥14)	5.13 (1.50-17.55)	<.01^e	3.70 (0.96-14.29)	.06	5.44 (1.58-18.71)	<.01^e
Severe depressive symptoms (PHQ-9 ≥10)	4.80 (1.45-15.87)	.01^e	2.96 (0.69-12.72)	.14	5.29 (1.20-23.30)	.03^e
Severe anxiety symptoms (GAD-7 ≥10)	1.64 (0.44-6.14)	.46	4.67 (0.98-22.25)	.05	16.80 (1.90-148.64)	.01

Factor

SD in Women (n = 36)^a

SD in Men (n = 13)^a

ED in Men (n = 22)^b

Univariable Analysis (95% CI)

P Value

Univariable Analysis (95% CI)

P Value

Univariable Analysis (95% CI)

P Value

Age

1.03 (0.99-1.07)

.15

1.00 (0.96-1.05)

.88

1.02 (0.98-1.07)

.26

Body mass index

0.99 (0.91-1.08)

.81

0.93 (0.79-1.11)

.42

0.96 (0.85-1.13)

.77

Long-term relationship (≥1 y)

1.56 (0.09-26.47)

.76

>1000 (0.00 -)

1.00

>1000 (0.00 -)

1.00

Crohn’s disease vs ulcerative colitis

0.77 (0.25-2.37)

.65

1.34 (0.38-4.73)

.65

2.26 (0.75-6.83)

.15

Disease duration

1.04 (0.98-1.09)

.19

0.89 (0.94-1.06)

.89

1.00 (0.95-1.05)

.92

Current corticosteroid use

1.08 (0.23-5.01)

.93

2.00 (0.43-9.42)

.38

0.82 (0.18-3.65)

.79

Corticosteroid use in year

0.78 (0.26-2.35)

.65

2.25 (0.60-8.41)

.23

1.69 (0.51-5.56)

.39

Immunomodulator use

0.48 (0.16-1.42)

.18

0.81 (0.23-2.87)

.75

0.91 (0.31-2.65)

.86

Anti-tumor necrosis factor use

1.39 (0.41-4.74)

.60

1.67 (0.37-7.65)

.51

1.15 (0.29-4.62)

.85

Psychotropic medication use

1.80 (0.54-6.03)

.34

3.15 (0.61-16.37)

.17

2.75 (0.55-13.67)

.22

Antihypertensive use

—

1.43 (0.32-6.38)

.64

2.64 (0.70-10.03)

.15

Opiate use

0.62 (0.08-4.72)

.64

—

Other major comorbidityc

1.39 (0.41-4.74)

.60

3.64 (0.81-16.33)

.09

2.43 (0.58-10.23)

.23

Prior diagnosis of anxiety or depression

1.80 (0.54-6.03)

.34

2.61 (0.39-17.56)

.33

2.76 (0.42-18.01)

.29

Irritable bowel syndrome

1.69 (0.30-9.56)

.55

—

Current smoking

0.61 (0.11-3.30)

.56

4.88 (0.28-86.35)

.28

1.85 (0.11-31.12)

.67

Excess alcohol intaked

1.44 (0.12-17.12)

.77

—

Previous abdominal surgery

5.33 (1.34-21.20)

.02^e

0.76 (0.18-3.22)

.71

0.70 (0.21-2.36)

.56

Hormonal contraceptive use

0.77 (0.18-3.21)

.72

—

Current or previous perianal disease

6.56 (0.72-59.85)

.10

0.75 (0.07-7.88)

.81

0.25 (0.03-2.53)

.24

Baseline Hb

0.98 (0.93-1.02)

.30

0.94 (0.89-0.98)

.01^e

0.95 (0.90-0.99)

.02

Elevated baseline fCal (≥200 μg/g)

1.19 (0.39-3.59)

.76

0.86 (0.24-3.03)

.81

0.81 (0.27-2.41)

.70

Active IBD symptoms (HBI ≥5, SCCAI ≥5)

3.21 (1.03-9.98)

.04^e

0.68 (0.19-2.40)

.55

0.98 (0.34-2.83)

.97

Active endoscopic disease (SES-CD ≥3, UCEIS ≥2)

1.62 (0.56-4.70)

.37

0.44 (0.12-1.55)

.20

0.57 (0.20-1.65)

.30

Reduced quality of life (IBDQ-32 <169)

2.29 (0.76-6.88)

.139

1.29 (0.36-4.63)

.69

1.64 (0.54-4.94)

.38

Moderate or severe stress symptoms (PSS-10 ≥14)

5.13 (1.50-17.55)

<.01^e

3.70 (0.96-14.29)

.06

5.44 (1.58-18.71)

<.01^e

Severe depressive symptoms (PHQ-9 ≥10)

4.80 (1.45-15.87)

.01^e

2.96 (0.69-12.72)

.14

5.29 (1.20-23.30)

.03^e

Severe anxiety symptoms (GAD-7 ≥10)

1.64 (0.44-6.14)

.46

4.67 (0.98-22.25)

.05

16.80 (1.90-148.64)

.01

Factor	SD in Women (n = 36)^a	SD in Men (n = 13)^a	ED in Men (n = 22)^b
Age	1.03 (0.99-1.07)	.15	1.00 (0.96-1.05)	.88	1.02 (0.98-1.07)	.26
Body mass index	0.99 (0.91-1.08)	.81	0.93 (0.79-1.11)	.42	0.96 (0.85-1.13)	.77
Long-term relationship (≥1 y)	1.56 (0.09-26.47)	.76	>1000 (0.00 -)	1.00	>1000 (0.00 -)	1.00
Crohn’s disease vs ulcerative colitis	0.77 (0.25-2.37)	.65	1.34 (0.38-4.73)	.65	2.26 (0.75-6.83)	.15
Disease duration	1.04 (0.98-1.09)	.19	0.89 (0.94-1.06)	.89	1.00 (0.95-1.05)	.92
Current corticosteroid use	1.08 (0.23-5.01)	.93	2.00 (0.43-9.42)	.38	0.82 (0.18-3.65)	.79
Corticosteroid use in year	0.78 (0.26-2.35)	.65	2.25 (0.60-8.41)	.23	1.69 (0.51-5.56)	.39
Immunomodulator use	0.48 (0.16-1.42)	.18	0.81 (0.23-2.87)	.75	0.91 (0.31-2.65)	.86
Anti-tumor necrosis factor use	1.39 (0.41-4.74)	.60	1.67 (0.37-7.65)	.51	1.15 (0.29-4.62)	.85
Psychotropic medication use	1.80 (0.54-6.03)	.34	3.15 (0.61-16.37)	.17	2.75 (0.55-13.67)	.22
Antihypertensive use	—	—	1.43 (0.32-6.38)	.64	2.64 (0.70-10.03)	.15
Opiate use	0.62 (0.08-4.72)	.64	—	—	—	—
Other major comorbidityc	1.39 (0.41-4.74)	.60	3.64 (0.81-16.33)	.09	2.43 (0.58-10.23)	.23
Prior diagnosis of anxiety or depression	1.80 (0.54-6.03)	.34	2.61 (0.39-17.56)	.33	2.76 (0.42-18.01)	.29
Irritable bowel syndrome	1.69 (0.30-9.56)	.55	—	—	—	—
Current smoking	0.61 (0.11-3.30)	.56	4.88 (0.28-86.35)	.28	1.85 (0.11-31.12)	.67
Excess alcohol intaked	1.44 (0.12-17.12)	.77	—	—	—	—
Previous abdominal surgery	5.33 (1.34-21.20)	.02^e	0.76 (0.18-3.22)	.71	0.70 (0.21-2.36)	.56
Hormonal contraceptive use	0.77 (0.18-3.21)	.72	—	—	—	—
Current or previous perianal disease	6.56 (0.72-59.85)	.10	0.75 (0.07-7.88)	.81	0.25 (0.03-2.53)	.24
Baseline Hb	0.98 (0.93-1.02)	.30	0.94 (0.89-0.98)	.01^e	0.95 (0.90-0.99)	.02
Elevated baseline fCal (≥200 μg/g)	1.19 (0.39-3.59)	.76	0.86 (0.24-3.03)	.81	0.81 (0.27-2.41)	.70
Active IBD symptoms (HBI ≥5, SCCAI ≥5)	3.21 (1.03-9.98)	.04^e	0.68 (0.19-2.40)	.55	0.98 (0.34-2.83)	.97
Active endoscopic disease (SES-CD ≥3, UCEIS ≥2)	1.62 (0.56-4.70)	.37	0.44 (0.12-1.55)	.20	0.57 (0.20-1.65)	.30
Reduced quality of life (IBDQ-32 <169)	2.29 (0.76-6.88)	.139	1.29 (0.36-4.63)	.69	1.64 (0.54-4.94)	.38
Moderate or severe stress symptoms (PSS-10 ≥14)	5.13 (1.50-17.55)	<.01^e	3.70 (0.96-14.29)	.06	5.44 (1.58-18.71)	<.01^e
Severe depressive symptoms (PHQ-9 ≥10)	4.80 (1.45-15.87)	.01^e	2.96 (0.69-12.72)	.14	5.29 (1.20-23.30)	.03^e
Severe anxiety symptoms (GAD-7 ≥10)	1.64 (0.44-6.14)	.46	4.67 (0.98-22.25)	.05	16.80 (1.90-148.64)	.01

Factor

SD in Women (n = 36)^a

SD in Men (n = 13)^a

ED in Men (n = 22)^b

Univariable Analysis (95% CI)

P Value

Univariable Analysis (95% CI)

P Value

Univariable Analysis (95% CI)

P Value

Age

1.03 (0.99-1.07)

.15

1.00 (0.96-1.05)

.88

1.02 (0.98-1.07)

.26

Body mass index

0.99 (0.91-1.08)

.81

0.93 (0.79-1.11)

.42

0.96 (0.85-1.13)

.77

Long-term relationship (≥1 y)

1.56 (0.09-26.47)

.76

>1000 (0.00 -)

1.00

>1000 (0.00 -)

1.00

Crohn’s disease vs ulcerative colitis

0.77 (0.25-2.37)

.65

1.34 (0.38-4.73)

.65

2.26 (0.75-6.83)

.15

Disease duration

1.04 (0.98-1.09)

.19

0.89 (0.94-1.06)

.89

1.00 (0.95-1.05)

.92

Current corticosteroid use

1.08 (0.23-5.01)

.93

2.00 (0.43-9.42)

.38

0.82 (0.18-3.65)

.79

Corticosteroid use in year

0.78 (0.26-2.35)

.65

2.25 (0.60-8.41)

.23

1.69 (0.51-5.56)

.39

Immunomodulator use

0.48 (0.16-1.42)

.18

0.81 (0.23-2.87)

.75

0.91 (0.31-2.65)

.86

Anti-tumor necrosis factor use

1.39 (0.41-4.74)

.60

1.67 (0.37-7.65)

.51

1.15 (0.29-4.62)

.85

Psychotropic medication use

1.80 (0.54-6.03)

.34

3.15 (0.61-16.37)

.17

2.75 (0.55-13.67)

.22

Antihypertensive use

—

1.43 (0.32-6.38)

.64

2.64 (0.70-10.03)

.15

Opiate use

0.62 (0.08-4.72)

.64

—

Other major comorbidityc

1.39 (0.41-4.74)

.60

3.64 (0.81-16.33)

.09

2.43 (0.58-10.23)

.23

Prior diagnosis of anxiety or depression

1.80 (0.54-6.03)

.34

2.61 (0.39-17.56)

.33

2.76 (0.42-18.01)

.29

Irritable bowel syndrome

1.69 (0.30-9.56)

.55

—

Current smoking

0.61 (0.11-3.30)

.56

4.88 (0.28-86.35)

.28

1.85 (0.11-31.12)

.67

Excess alcohol intaked

1.44 (0.12-17.12)

.77

—

Previous abdominal surgery

5.33 (1.34-21.20)

.02^e

0.76 (0.18-3.22)

.71

0.70 (0.21-2.36)

.56

Hormonal contraceptive use

0.77 (0.18-3.21)

.72

—

Current or previous perianal disease

6.56 (0.72-59.85)

.10

0.75 (0.07-7.88)

.81

0.25 (0.03-2.53)

.24

Baseline Hb

0.98 (0.93-1.02)

.30

0.94 (0.89-0.98)

.01^e

0.95 (0.90-0.99)

.02

Elevated baseline fCal (≥200 μg/g)

1.19 (0.39-3.59)

.76

0.86 (0.24-3.03)

.81

0.81 (0.27-2.41)

.70

Active IBD symptoms (HBI ≥5, SCCAI ≥5)

3.21 (1.03-9.98)

.04^e

0.68 (0.19-2.40)

.55

0.98 (0.34-2.83)

.97

Active endoscopic disease (SES-CD ≥3, UCEIS ≥2)

1.62 (0.56-4.70)

.37

0.44 (0.12-1.55)

.20

0.57 (0.20-1.65)

.30

Reduced quality of life (IBDQ-32 <169)

2.29 (0.76-6.88)

.139

1.29 (0.36-4.63)

.69

1.64 (0.54-4.94)

.38

Moderate or severe stress symptoms (PSS-10 ≥14)

5.13 (1.50-17.55)

<.01^e

3.70 (0.96-14.29)

.06

5.44 (1.58-18.71)

<.01^e

Severe depressive symptoms (PHQ-9 ≥10)

4.80 (1.45-15.87)

.01^e

2.96 (0.69-12.72)

.14

5.29 (1.20-23.30)

.03^e

Severe anxiety symptoms (GAD-7 ≥10)

1.64 (0.44-6.14)

.46

4.67 (0.98-22.25)

.05

16.80 (1.90-148.64)

.01

Table 3.

Open in new tab

Logistic regression analyses assessing factors associated with SD in women and men and ED in men with IBD

Factor	SD in Women (n = 36)^a		SD in Men (n = 13)^a		ED in Men (n = 22)^b
Factor	Univariable Analysis (95% CI)	P Value	Univariable Analysis (95% CI)	P Value	Univariable Analysis (95% CI)	P Value
Age	1.03 (0.99-1.07)	.15	1.00 (0.96-1.05)	.88	1.02 (0.98-1.07)	.26
Body mass index	0.99 (0.91-1.08)	.81	0.93 (0.79-1.11)	.42	0.96 (0.85-1.13)	.77
Long-term relationship (≥1 y)	1.56 (0.09-26.47)	.76	>1000 (0.00 -)	1.00	>1000 (0.00 -)	1.00
Crohn’s disease vs ulcerative colitis	0.77 (0.25-2.37)	.65	1.34 (0.38-4.73)	.65	2.26 (0.75-6.83)	.15
Disease duration	1.04 (0.98-1.09)	.19	0.89 (0.94-1.06)	.89	1.00 (0.95-1.05)	.92
Current corticosteroid use	1.08 (0.23-5.01)	.93	2.00 (0.43-9.42)	.38	0.82 (0.18-3.65)	.79
Corticosteroid use in year	0.78 (0.26-2.35)	.65	2.25 (0.60-8.41)	.23	1.69 (0.51-5.56)	.39
Immunomodulator use	0.48 (0.16-1.42)	.18	0.81 (0.23-2.87)	.75	0.91 (0.31-2.65)	.86
Anti-tumor necrosis factor use	1.39 (0.41-4.74)	.60	1.67 (0.37-7.65)	.51	1.15 (0.29-4.62)	.85
Psychotropic medication use	1.80 (0.54-6.03)	.34	3.15 (0.61-16.37)	.17	2.75 (0.55-13.67)	.22
Antihypertensive use	—	—	1.43 (0.32-6.38)	.64	2.64 (0.70-10.03)	.15
Opiate use	0.62 (0.08-4.72)	.64	—	—	—	—
Other major comorbidityc	1.39 (0.41-4.74)	.60	3.64 (0.81-16.33)	.09	2.43 (0.58-10.23)	.23
Prior diagnosis of anxiety or depression	1.80 (0.54-6.03)	.34	2.61 (0.39-17.56)	.33	2.76 (0.42-18.01)	.29
Irritable bowel syndrome	1.69 (0.30-9.56)	.55	—	—	—	—
Current smoking	0.61 (0.11-3.30)	.56	4.88 (0.28-86.35)	.28	1.85 (0.11-31.12)	.67
Excess alcohol intaked	1.44 (0.12-17.12)	.77	—	—	—	—
Previous abdominal surgery	5.33 (1.34-21.20)	.02^e	0.76 (0.18-3.22)	.71	0.70 (0.21-2.36)	.56
Hormonal contraceptive use	0.77 (0.18-3.21)	.72	—	—	—	—
Current or previous perianal disease	6.56 (0.72-59.85)	.10	0.75 (0.07-7.88)	.81	0.25 (0.03-2.53)	.24
Baseline Hb	0.98 (0.93-1.02)	.30	0.94 (0.89-0.98)	.01^e	0.95 (0.90-0.99)	.02
Elevated baseline fCal (≥200 μg/g)	1.19 (0.39-3.59)	.76	0.86 (0.24-3.03)	.81	0.81 (0.27-2.41)	.70
Active IBD symptoms (HBI ≥5, SCCAI ≥5)	3.21 (1.03-9.98)	.04^e	0.68 (0.19-2.40)	.55	0.98 (0.34-2.83)	.97
Active endoscopic disease (SES-CD ≥3, UCEIS ≥2)	1.62 (0.56-4.70)	.37	0.44 (0.12-1.55)	.20	0.57 (0.20-1.65)	.30
Reduced quality of life (IBDQ-32 <169)	2.29 (0.76-6.88)	.139	1.29 (0.36-4.63)	.69	1.64 (0.54-4.94)	.38
Moderate or severe stress symptoms (PSS-10 ≥14)	5.13 (1.50-17.55)	<.01^e	3.70 (0.96-14.29)	.06	5.44 (1.58-18.71)	<.01^e
Severe depressive symptoms (PHQ-9 ≥10)	4.80 (1.45-15.87)	.01^e	2.96 (0.69-12.72)	.14	5.29 (1.20-23.30)	.03^e
Severe anxiety symptoms (GAD-7 ≥10)	1.64 (0.44-6.14)	.46	4.67 (0.98-22.25)	.05	16.80 (1.90-148.64)	.01

Factor	SD in Women (n = 36)^a		SD in Men (n = 13)^a		ED in Men (n = 22)^b
Factor	Univariable Analysis (95% CI)	P Value	Univariable Analysis (95% CI)	P Value	Univariable Analysis (95% CI)	P Value
Age	1.03 (0.99-1.07)	.15	1.00 (0.96-1.05)	.88	1.02 (0.98-1.07)	.26
Body mass index	0.99 (0.91-1.08)	.81	0.93 (0.79-1.11)	.42	0.96 (0.85-1.13)	.77
Long-term relationship (≥1 y)	1.56 (0.09-26.47)	.76	>1000 (0.00 -)	1.00	>1000 (0.00 -)	1.00
Crohn’s disease vs ulcerative colitis	0.77 (0.25-2.37)	.65	1.34 (0.38-4.73)	.65	2.26 (0.75-6.83)	.15
Disease duration	1.04 (0.98-1.09)	.19	0.89 (0.94-1.06)	.89	1.00 (0.95-1.05)	.92
Current corticosteroid use	1.08 (0.23-5.01)	.93	2.00 (0.43-9.42)	.38	0.82 (0.18-3.65)	.79
Corticosteroid use in year	0.78 (0.26-2.35)	.65	2.25 (0.60-8.41)	.23	1.69 (0.51-5.56)	.39
Immunomodulator use	0.48 (0.16-1.42)	.18	0.81 (0.23-2.87)	.75	0.91 (0.31-2.65)	.86
Anti-tumor necrosis factor use	1.39 (0.41-4.74)	.60	1.67 (0.37-7.65)	.51	1.15 (0.29-4.62)	.85
Psychotropic medication use	1.80 (0.54-6.03)	.34	3.15 (0.61-16.37)	.17	2.75 (0.55-13.67)	.22
Antihypertensive use	—	—	1.43 (0.32-6.38)	.64	2.64 (0.70-10.03)	.15
Opiate use	0.62 (0.08-4.72)	.64	—	—	—	—
Other major comorbidityc	1.39 (0.41-4.74)	.60	3.64 (0.81-16.33)	.09	2.43 (0.58-10.23)	.23
Prior diagnosis of anxiety or depression	1.80 (0.54-6.03)	.34	2.61 (0.39-17.56)	.33	2.76 (0.42-18.01)	.29
Irritable bowel syndrome	1.69 (0.30-9.56)	.55	—	—	—	—
Current smoking	0.61 (0.11-3.30)	.56	4.88 (0.28-86.35)	.28	1.85 (0.11-31.12)	.67
Excess alcohol intaked	1.44 (0.12-17.12)	.77	—	—	—	—
Previous abdominal surgery	5.33 (1.34-21.20)	.02^e	0.76 (0.18-3.22)	.71	0.70 (0.21-2.36)	.56
Hormonal contraceptive use	0.77 (0.18-3.21)	.72	—	—	—	—
Current or previous perianal disease	6.56 (0.72-59.85)	.10	0.75 (0.07-7.88)	.81	0.25 (0.03-2.53)	.24
Baseline Hb	0.98 (0.93-1.02)	.30	0.94 (0.89-0.98)	.01^e	0.95 (0.90-0.99)	.02
Elevated baseline fCal (≥200 μg/g)	1.19 (0.39-3.59)	.76	0.86 (0.24-3.03)	.81	0.81 (0.27-2.41)	.70
Active IBD symptoms (HBI ≥5, SCCAI ≥5)	3.21 (1.03-9.98)	.04^e	0.68 (0.19-2.40)	.55	0.98 (0.34-2.83)	.97
Active endoscopic disease (SES-CD ≥3, UCEIS ≥2)	1.62 (0.56-4.70)	.37	0.44 (0.12-1.55)	.20	0.57 (0.20-1.65)	.30
Reduced quality of life (IBDQ-32 <169)	2.29 (0.76-6.88)	.139	1.29 (0.36-4.63)	.69	1.64 (0.54-4.94)	.38
Moderate or severe stress symptoms (PSS-10 ≥14)	5.13 (1.50-17.55)	<.01^e	3.70 (0.96-14.29)	.06	5.44 (1.58-18.71)	<.01^e
Severe depressive symptoms (PHQ-9 ≥10)	4.80 (1.45-15.87)	.01^e	2.96 (0.69-12.72)	.14	5.29 (1.20-23.30)	.03^e
Severe anxiety symptoms (GAD-7 ≥10)	1.64 (0.44-6.14)	.46	4.67 (0.98-22.25)	.05	16.80 (1.90-148.64)	.01

Abbreviations: CI, confidence interval; CRP, C-reactive protein; ED, erectile dysfunction; fCal, fecal calprotectin; FSFI, Female Sexual Function Index; GAD-7, Generalized Anxiety Disorder-7; Hb, hemoglobin; HBI, Harvey-Bradshaw index; IBD, inflammatory bowel disease; IBDQ-32, Inflammatory Bowel Disease Questionnaire-32; IIEF, International Index of Erectile Function; PHQ-9, Patient Health Questionnaire-9; PSS-10, Perceived Stress Scale 10; SCCAI, Simple Clinical Colitis Activity Index; SD, sexual dysfunction; SES-CD, Simple Endoscopic Score for Crohn’s Disease; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

^aFSFI ≤26.55 and IIEF ≤42.9.

^bED domain score of IIEF ≤26.

^cChronic respiratory, cardiac, gastrointestinal (excluding IBD and irritable bowel syndrome), gynecological condition, or current/previous malignancy (excluding squamous cell skin cancer or basal cell skin cancer).

^d≥14 units/week (women); ≥21 units/week (men).

^eSelected for multivariable analysis.

This Feature Is Available To Subscribers Only